Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
Authors' conclusion
Compared with TAT, DAT shows a reduction in TIMI major or minor bleeding by 47% with comparable outcomes of MACE.
Study context
- Population
- Patients with atrial fibrillation (AF) following percutaneous coronary intervention (PCI)
- Participants
- 5,317 patients4 RCTs
- Comparison
- Dual vs triple antithrombotic therapy
- DATn = 3,039
- Outcome
- Safety (TIMI major or minor bleeding) and efficacy (trial-defined MACE)
Methodological detailsPhase 3 trials
- Phase 3 trials
Pooled result
Trial-defined MACE
Hazard ratio
0.85
95% CrI 0.48–1.29
By group
DATvs TAT
HR 0.85 (95% CrI 0.48–1.29)
As reported in the abstract
Further pooled results
All-cause mortality, cardiac death, MI, stent thrombosis, stroke
- No difference between the two arms
Safety
| Outcome | DAT | TAT | HR (95% CrI) | |
|---|---|---|---|---|
| TIMI major or minor bleedingI2 = 42.9% · CrI | 4.3% | 9.0% | 0.53 (0.36–0.85) | |
| 0.20.5125Hazard ratio (log scale) |
Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding
- Reduction by 47% with DAT
Original publication
Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. Published 13 April 2018. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →